Skip to main content
All Posts By

Support

ResearchTreatments

Efficacy and Safety of Patritumab Deruxtecan in EGFR Mutated NSCLC Resistant to EGFR TKI Therapy

*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker, achieved clinically meaningful, durable efficacy in a phase I dose escalation and dose expansion study conducted in patients with locally…
Support
September 7, 2021
ResearchTreatments

Amivantamab & Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC

*July 2021* Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the CHRYSALIS trial presented at the 2021 ASCO Annual Meeting.1 The study…
Support
September 7, 2021
ResearchTreatments

Experts Break Down Exciting Breakthroughs in NSCLC

*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and set the stage for further research aimed at generating better tolerated, more effective, and optimally sequenced treatments. Nicholas C. Rohs, MD, an assistant professor of medicine, hematology, and medical oncology at…
Support
September 6, 2021